GSK’s oncology business suffers another blow with Zejula setback

News follows setback for GSK’s blood cancer drug Blenrep Shares fall nearly 5% in afternoon trading Nov 11 (Reuters) – Britain’s GSK said on Friday it would limit the use of its ovarian cancer drug Zejula in the United States as a second treatment option to ward off cancer in patients whose tumors carry certain … Read more